IOVA Q1 2021 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$76M

Net Income

-$75M

EPS (Diluted)

$-0.51

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$73M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$751M

Total Liabilities

$103M

Stockholders' Equity

$647M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$76M	-$71M	-6.7%
Net Income	-$75M	-$70M	-8.4%